glp 1 for cardiovascular disease GLP-1 Agonists in Diseases: Mechanisms, Clinical Evidence, and Emerging Therapies GLP-1 receptor agonists and cardiovascular

Generally, clients notice a discernible shift in their hunger cues within the first 3 to 7 days of their first dose

While their primary role is to assist with weight reduction, the advantages of GLP-1 therapy extend well beyond the number on the scale

Cardiovascular event reduction has also been observed in type 1 populations at higher metabolic risk

Orals are also being launched I think it was over estimated for the short term and now being underestimated for the long term Mounjaro has become 0.8-0.9 % of the indian market no other drug is even half of it and that it in about 18 months

I was getting phone callsupdates and making appointments

S.SodhiP.GuptaK